Pmv Pharmaceuticals, Inc. ( (PMVP) ) has released its Q3 earnings. Here is a breakdown of the information Pmv Pharmaceuticals, Inc. presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
PMV Pharmaceuticals, Inc. is a precision oncology company focused on developing small molecule therapies targeting p53 mutations, headquartered in Princeton, New Jersey. In its latest earnings report for the quarter ended September 30, 2025, PMV Pharmaceuticals reported a net loss of $21.1 million, compared to a net loss of $19.2 million in the same period last year. The company’s total operating expenses increased to $22.5 million, driven by higher research and development costs. Despite the losses, PMV Pharmaceuticals maintains a strong cash position with $129.3 million in cash, cash equivalents, and marketable securities, providing a runway for continued operations. Looking ahead, PMV Pharmaceuticals plans to focus on advancing its product candidates through clinical trials, with the management expressing confidence in their strategic plans and financial position to support ongoing research and development activities.